Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. on November 2, 2016. The filing serves to announce the company's financial results for the third quarter ended September 30, 2016.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. It solely references the issuance of a press release containing the third-quarter results.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, or specific risk factors. It includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release dated November 2, 2016) for specific Q3 2016 financial figures.
- Verify the company's full name and ticker status, as the filing header lists "Pacira Pharmaceuticals, Inc." while the metadata indicates "Pacira Biosciences, Inc."
- Confirm the exact date of the press release distribution to ensure alignment with the November 2, 2016 filing date.